keyword
MENU ▼
Read by QxMD icon Read
search

Nafld nash

keyword
https://www.readbyqxmd.com/read/28214827/potential-regulators-driving-the-transition-in-nonalcoholic-fatty-liver-disease-a-stage-based-view
#1
Yi Lou, Yi-Dan Chen, Fu-Rong Sun, Jun-Ping Shi, Yu Song, Jin Yang
BACKGROUND AND AIM: The incidence of nonalcoholic fatty liver disease (NAFLD), ranging from mild steatosis to hepatocellular injury and inflammation, increases with the rise of obesity. However, the implications of transcription factors network in progressive NAFLD remain to be determined. METHODS: A co-regulatory network approach by combining gene expression and transcription influence was utilized to dissect transcriptional regulators in different NAFLD stages...
January 30, 2017: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/28214020/serum-uric-acid-concentrations-and-fructose-consumption-are-independently-associated-with-nash-in-children-and-adolescents
#2
Antonella Mosca, Valerio Nobili, Rita De Vito, Annalisa Crudele, Eleonora Scorletti, Alberto Villani, Anna Alisi, Christopher D Byrne
BACKGROUND & AIMS: Recent research has suggested that dietary fructose intake may increase serum uric acid (UA) concentrations. Both UA concentration and fructose consumption maybe also increase in NAFLD. It is not known whether dietary fructose consumption and UA concentration are independently associated with non-alcoholic steatohepatitis (NASH). Our aim was to investigate the factors associated with NASH in children and adolescents with proven NAFLD, and to test whether UA concentrations and fructose consumption are independently associated with NASH...
February 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28211165/a-disease-specific-quality-of-life-instrument-for-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis-cldq-nafld
#3
Zobair M Younossi, Maria Stepanova, Linda Henry, Andrei Racila, Brian Lam, Huong T Pham, Sharon Hunt
BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease with known negative impact on patients' health-related quality of life (HRQL). Our aim was to validate a disease-specific HRQL instrument useful for efficacy trials involving patients with NAFLD and NASH. METHODS: From a long item selection questionnaire, we selected relevant items which, by factor analysis, were grouped into domains constituting CLDQ-NAFLD...
February 17, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28206970/genetic-variation-in-long-noncoding-rnas-and-the-risk-of-nonalcoholic-fatty-liver-disease
#4
Silvia Sookoian, Cristian Rohr, Adrián Salatino, Hernán Dopazo, Tomas Fernandez Gianotti, Gustavo O Castaño, Carlos J Pirola
: The human transcriptome comprises a myriad of non protein-coding RNA species, including long noncoding RNAs (lncRNAs), which have a remarkable role in transcriptional and epigenetic regulation. We hypothesized that variants in lncRNAs influence the susceptibility to nonalcoholic fatty liver disease (NAFLD). Using next generation sequencing, we performed a survey of genetic variation associated with randomly selected lncRNA-genomic regions located within both experimentally validated and computationally predicted regulatory elements...
February 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28195199/pemafibrate-a-novel-selective-peroxisome-proliferator-activated-receptor-alpha-modulator-improves-the-pathogenesis-in-a-rodent-model-of-nonalcoholic-steatohepatitis
#5
Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Toshiaki Takizawa, Satoru Saito, Yoji Nagashima, Atsushi Nakajima
The efficacy of peroxisome proliferator-activated receptor α-agonists (e.g., fibrates) against nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) in humans is not known. Pemafibrate is a novel selective peroxisome proliferator-activated receptor α modulator that can maximize the beneficial effects and minimize the adverse effects of fibrates used currently. In a phase-2 study, pemafibrate was shown to improve liver dysfunction in patients with dyslipidaemia. In the present study, we first investigated the effect of pemafibrate on rodent models of NASH...
February 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28195177/prevalence-of-nonalcoholic-steatohepatitis-associated-cirrhosis-in-the-united-states-an-analysis-of-national-health-and-nutrition-examination-survey-data
#6
Mohammad Nasser Kabbany, Praveen Kumar Conjeevaram Selvakumar, Kymberly Watt, Rocio Lopez, Zade Akras, Nizar Zein, William Carey, Naim Alkhouri
OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of manifestations ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), fibrosis and eventually cirrhosis. The prevalence of NAFLD has been shown to be increasing over time; however, the prevalence of NASH cirrhosis and advanced fibrosis over time has not been well studied. Estimate the changes in prevalence of NASH cirrhosis and NAFLD-associated advanced fibrosis among adults in the United States...
February 14, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28177674/exercise-restores-bioavailability-of-hydrogen-sulfide-and-promotes-autophagy-influx-in-livers-of-mice-fed-with-high-fat-diet
#7
Bing Wang, Jing Zeng, Qi Gu
In the gold standard treatment for non-alcoholic fatty liver disease (NAFLD), exercise training has been shown to effectively improve NASH. However, limited data are available about the underlying mechanisms involved. This work was undertaken to investigate the mechanisms underlying the beneficial effect of exercise training on high-fat diet (HFD)-induced NAFLD in mice. Male mice were fed with HFD and given moderate-intensity exercise for 24 weeks. Exercise training lowered weight gain, attenuated systemic insulin resistance and glucose intolerance, mitigated hepatic steatosis and fibrosis in mice fed with HFD...
January 10, 2017: Canadian Journal of Physiology and Pharmacology
https://www.readbyqxmd.com/read/28167322/-nlrp3-inflammasome-blockade-reduces-liver-inflammation-and-fibrosis-in-experimental-nash-in-mice
#8
Auvro R Mridha, Alexander Wree, Avril A B Robertson, Matthew M Yeh, Casey D Johnson, Derrick M Van Rooyen, Fahrettin Haczeyni, Narci C-H Teoh, Christopher Savard, George N Ioannou, Seth L Masters, Kate Schroder, Matthew A Cooper, Ariel E Feldstein, Geoffrey C Farrell
BACKGROUND AND AIMS: NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in NAFLD. We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. METHODS: We fed foz/foz and wildtype (Wt) mice atherogenic diet 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determining NAFLD phenotype. In mice fed methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle 6 weeks and determined effects on liver fibrosis...
February 3, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/28155087/the-association-between-helicobacter-pylori-infection-and-nonalcoholic-fatty-liver-disease
#9
REVIEW
Derek M Tang, Sheila Kumar
PURPOSE OF REVIEW: Helicobacter pylori (HP) infection is known to be a significant risk factor in the development of certain gastric conditions, such as ulcers, gastritis, and malignancy. Recently, however, the systemic effect of HP infection on other organ systems has come to be appreciated. In this review, we will explore the association between HP infection and nonalcoholic fatty liver disease (NAFLD), the hepatic component of metabolic syndrome. RECENT FINDINGS: The possible association between HP infection and NAFLD initially stemmed from the isolation of HP bacteria in the livers of patients with NAFLD...
February 2017: Current Gastroenterology Reports
https://www.readbyqxmd.com/read/28154266/the-serum-oxidative-anti-oxidative-stress-balance-becomes-dysregulated-in-patients-with-non-alcoholic-steatohepatitis-associated-with-hepatocellular-carcinoma
#10
Yasuyuki Shimomura, Akinobu Takaki, Nozomu Wada, Tetsuya Yasunaka, Fusao Ikeda, Takayuki Maruyama, Naofumi Tamaki, Daisuke Uchida, Hideki Onishi, Kenji Kuwaki, Shinichiro Nakamura, Kazuhiro Nouso, Yasuhiro Miyake, Kazuko Koike, Takaaki Tomofuji, Manabu Morita, Kazuhide Yamamoto, Hiroyuki Okada
Objective Oxidative stress is associated with the progression of chronic liver disease. Non-alcoholic fatty liver disease (NAFLD) is also an oxidative stress-related disease. However, the oxidative/anti-oxidative balance has not been fully characterized in NAFLD. The objective of the present study was to investigate the balance between oxidative stress and the anti-oxidative activity in NAFLD, including non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC). Patients We recruited 69 patients with histologically proven NAFLD without HCC (NAFLD; n=58), and with NASH-related HCC (NASH-HCC; n=11)...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28148637/impact-of-nonalcoholic-fatty-liver-disease-on-toxicokinetics-of-tetrachloroethylene
#11
Joseph A Cichocki, Shinji Furuya, Kranti Konganti, Yu-Syuan Luo, Thomas J McDonald, Yasuhiro Iwata, Weihsueh A Chiu, David W Threadgill, Igor P Pogribny, Ivan Rusyn
Lifestyle factors and chronic pathological states are important contributors to inter-individual variability in susceptibility to xenobiotic-induced toxicity. Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent condition that can dramatically affect chemical metabolism. We examined the effect of NAFLD on toxicokinetics of tetrachloroethylene (PERC), a ubiquitous environmental contaminant that requires metabolic activation to induce adverse health effects. Mice (C57Bl/6J, male) were fed a low-fat diet (LFD), high fat diet (HFD), or methionine/folate/choline-deficient diet (MCD) to model a healthy liver, steatosis, or nonalcoholic steatohepatitis (NASH), respectively...
February 1, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28142119/ginkgolide-a-ameliorates-non-alcoholic-fatty-liver-diseases-on-high-fat-diet-mice
#12
Hyeon-Soo Jeong, Kang-Hoon Kim, In-Seung Lee, Ji Young Park, Yumi Kim, Ki-Suk Kim, Hyeung-Jin Jang
Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide and has continuously increased. NAFLD refers to a spectrum of diseases ranging from fatty liver to steatohepatitis, cirrhosis, and even to hepatocyte carcinoma. Excessive fatty acid enters the cell and the mitochondria undergo stress and unremoved ROS can trigger a form of cell apoptosis known as 'lipoapoptosis'. NASH arises from damaged liver hepatocytes due to lipotoxicity. NASH not only involves lipid accumulation and apoptosis but also inflammation...
January 28, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28133774/dual-photon-microscopy-based-quantitation-of-fibrosis-related-parameters-q-fp-to-model-disease-progression-in-steatohepatitis
#13
Yan Wang, Robert Vincent, Jinlian Yang, Amon Asgharpour, Xieer Liang, Michael O Idowu, Melissa J Contos, Kalyani Daitya, Mohammed S Siddiqui, Faridoddin Mirshahi, Arun J Sanyal
: There is a need for further refinement of current histological systems for assessment of hepatic fibrosis in nonalcoholic fatty liver disease (NAFLD). This study evaluated hepatic fibrosis in NAFLD using dual photon microscopy based quantitation of fibrosis-related parameters (q-FPs). Fifty (test cohort) and 42 (validation cohort) subjects with NAFLD and the full spectrum of fibrosis were studied. Q-FPs were measured in specific predefined regions of interest (general, vessel, perisinusoid and vascular septa)...
January 30, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28132890/metabolomic-identification-of-subtypes-of-nonalcoholic-steatohepatitis
#14
Cristina Alonso, David Fernández-Ramos, Marta Varela-Rey, Ibon Martínez-Arranz, Nicolás Navasa, Sebastiaan M Van Liempd, José L Lavin, Rebeca Mayo, Concetta P Ilisso, Virginia G de Juan, Marta Iruarrizaga-Lejarreta, Laura delaCruz-Villar, Itziar Mincholé, Aaron Robinson, Javier Crespo, Antonio Martín-Duce, Manuel Romero-Gomez, Holger Sann, Julian Platon, Jennifer Van Eyk, Patricia Aspichueta, Mazen Noureddin, Juan M Falcón-Pérez, Juan Anguita, Ana M Aransay, María Luz Martínez-Chantar, Shelly C Lu, José M Mato
BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is a consequence of defects in diverse metabolic pathways that involve hepatic accumulation of triglycerides. Features of these aberrations might determine whether NAFLD progresses to nonalcoholic steatohepatitis (NASH). We investigated whether the diverse defects observed in patients with NAFLD are due to different NAFLD subtypes with specific serum metabolomic profiles, and whether these can distinguish patients with NASH from patients with simple steatosis...
January 26, 2017: Gastroenterology
https://www.readbyqxmd.com/read/28130788/increased-risk-of-mortality-by-fibrosis-stage-in-non-alcoholic-fatty-liver-disease-systematic-review-and-meta-analysis
#15
Parambir S Dulai, Siddharth Singh, Janki Patel, Meera Soni, Larry J Prokop, Zobair Younossi, Giada Sebastiani, Mattias Ekstedt, Hannes Hagstrom, Patrik Nasr, Per Stal, Vincent Wai-Sun Wong, Stergios Kechagias, Rolf Hultcrantz, Rohit Loomba
BACKGROUND: Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease (NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically evaluated. We aimed to quantify the fibrosis stage-specific risk of all-cause and liver-related mortality in NAFLD. METHODS: Through a systematic review and meta-analysis, we identified 5 adult NAFLD cohort studies reporting fibrosis stage specific mortality (0-4). Using fibrosis stage 0 as a reference population, fibrosis stage-specific mortality rate ratios (MRR) with 95% confidence intervals (CI), for all-cause and liver-related mortality, were estimated...
January 28, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28125073/the-association-between-igf-1-levels-and-the-histologic-severity-of-nonalcoholic-fatty-liver-disease
#16
Laura E Dichtel, Kathleen E Corey, Joseph Misdraji, Miriam A Bredella, Melanie Schorr, Stephanie A Osganian, Brian J Young, Joshua C Sung, Karen K Miller
OBJECTIVES: The mechanisms responsible for the development of nonalcoholic fatty liver disease (NAFLD) and progression to nonalcoholic steatohepatitis (NASH) are incompletely understood. Growing evidence suggests that growth hormone (GH) and insulin-like growth factor-1 (IGF-1) may have roles in the development and progression of NAFLD. We hypothesized that lower serum IGF-1 levels would be associated with increased liver fat accumulation, inflammation, and fibrosis in a group of meticulously phenotyped obese subjects with liver biopsies...
January 26, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28123441/liver-mitochondrial-dna-copy-number-and-deletion-levels-may-contribute-to-nonalcoholic-fatty-liver-disease-susceptibility
#17
Sharareh Kamfar, Seyed Moayed Alavian, Massoud Houshmand, Reza Yadegarazari, Bahram Seifi Zarei, Alireza Khalaj, Noshin Shabab, Massoud Saidijam
BACKGROUND: There is growing evidence that deficiencies observed in the mitochondrial DNA (mtDNA) functions could play an important role in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We hypothesized that genetic variations in mtDNA could affect the mitochondrial function and contribute to the NAFLD susceptibility. OBJECTIVES: In this study, the possible association of the mtDNA copy number and 4,977-bp deletion levels with NAFLD susceptibility in a sample of Iranian population was evaluated...
December 2016: Hepatitis Monthly
https://www.readbyqxmd.com/read/28110193/effects-of-polyphenol-compounds-melanin-on-nafld-nash-prevention
#18
Natalia Belemets, Nazarii Kobyliak, Oleksandr Virchenko, Tetyana Falalyeyeva, Tsyryuk Olena, Petro Bodnar, Oleksiy Savchuk, Tetyana Galenova, Martin Caprnda, Luis Rodrigo, Lubomir Skladany, Delian Delev, Radka Opatrilova, Peter Kruzliak, Tetyana Beregova, Lyudmyla Ostapchenko
BACKGROUND: One of the pathogenic mechanisms of the progression non-alcoholic liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH) is the accumulation of reactive oxygen species (ROS). So, antioxidant therapy is necessary for successful treatment of the liver injury. We have paid attention to melanin produced by yeast Nadsoniella nigra strain X-1 as novel antioxidant and anti-inflammatory agents with low toxicity. In current study we aimed to investigate the preventive effect of melanin on the monosodium glutamate (MSG) induced NAFLD model in rats...
January 19, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28109892/lipid-oxidation-products-in-the-pathogenesis-of-non-alcoholic-steatohepatitis
#19
REVIEW
Francesco Bellanti, Rosanna Villani, Antonio Facciorusso, Gianluigi Vendemiale, Gaetano Serviddio
Non-alcoholic fatty liver disease (NAFLD) is the major public health challenge for hepatologists in the twenty-first century. NAFLD comprises a histological spectrum ranging from simple steatosis or fatty liver, to steatohepatitis, fibrosis, and cirrhosis. It can be categorized into two principal phenotypes: (1) non-alcoholic fatty liver (NAFL), and (2) non-alcoholic steatohepatitis (NASH). The mechanisms of NAFLD progression consist of lipid homeostasis alterations, redox unbalance, insulin resistance, and inflammation in the liver...
January 18, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/28104990/sitagliptin-in-patients-with-non-alcoholic-steatohepatitis-a-randomized-placebo-controlled-trial
#20
Tisha R Joy, Charles A McKenzie, Rommel G Tirona, Kelly Summers, Shannon Seney, Subrata Chakrabarti, Neel Malhotra, Melanie D Beaton
AIM: To evaluate the effect of sitagliptin vs placebo on histologic and non-histologic parameters of non-alcoholic steatohepatitis (NASH). METHODS: Twelve patients with biopsy-proven NASH were randomized to sitagliptin (100 mg daily) (n = 6) or placebo (n = 6) for 24 wk. The primary outcome was improvement in liver fibrosis after 24 wk. Secondary outcomes included evaluation of changes in NAFLD activity score (NAS), individual components of NAS (hepatocyte ballooning, lobular inflammation, and steatosis), glycemic control and insulin resistance [including measurements of glycated hemoglobin (HbA1C) and adipocytokines], lipid profile including free fatty acids, adipose distribution measured using magnetic resonance imaging (MRI), and thrombosis markers (platelet aggregation and plasminogen activator inhibitor 1 levels)...
January 7, 2017: World Journal of Gastroenterology: WJG
keyword
keyword
107637
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"